Penumbra, Inc. (PEN)
After hours:
| Previous close | 206.06 |
| Open | 208.81 |
| Bid | 203.29 x 800 |
| Ask | 214.32 x 800 |
| Day's range | 206.58 - 209.62 |
| 52-week range | 180.93 - 348.67 |
| Volume | |
| Avg. volume | 358,580 |
| Market cap | 8.083B |
| Beta (5Y monthly) | 0.53 |
| PE ratio (TTM) | 90.28 |
| EPS (TTM) | 2.31 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 277.38 |
PR NewswirePenumbra, Inc. to Present at the RBC Capital Markets Global Healthcare Conference
Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024.
ZacksPenumbra's (PEN) New Launch to Enhance Blood Clot Removal
Penumbra's (PEN) latest offering is likely to enable physicians to restore blood flow more quickly and further minimize blood loss.
PR NewswirePenumbra Launches Lightning Flash 2.0 - Latest CAVT Technology Designed to Rapidly Remove Blood Clots
Penumbra, Inc. (NYSE: PEN), the world's largest thrombectomy company, announced the U.S. Food and Drug Administration (FDA) clearance and launch of Lightning Flash™ 2.0, the next generation computer assisted vacuum thrombectomy (CAVT) system to remove venous thrombus and treat pulmonary emboli (PE). Lightning Flash 2.0 features advanced Lightning Flash algorithms, designed for increased speed and sensitivity to thrombus and blood flow. These new advancements combined with Penumbra's novel cathet
